Skip to content
Screener

Total Equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.53B+8.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$439.74M-30.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$613.98M-10.1%
Wave Life Sciences logo
Wave Life SciencesWVE
$453.52M+226%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$374.08M+44.8%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$493.2M+14.8%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 165,201,329 and 164,950,540 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1616
Additional paid-in capital2,382,1722,367,780
Accumulated other comprehensive loss (gain)(137)475
Accumulated deficit(1,516,996)(1,396,142)
Total stockholders’ equity865,055972,129
Total liabilities and stockholders’ equity$1,079,950$1,186,958

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s total equity?
Dyne Therapeutics, Inc. (DYN) reported total equity of $865.06M in Q1 2026.
How has Dyne Therapeutics, Inc.'s total equity changed year-over-year?
Dyne Therapeutics, Inc.'s total equity increased by 29.3% year-over-year, from $668.97M to $865.06M.
What is the long-term trend for Dyne Therapeutics, Inc.'s total equity?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s total equity has grown at a 23.2% compound annual growth rate (CAGR), from $342.37M to $972.13M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Dyne Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude